University of Vermont

College of Medicine

Office of Clinical Trials Research

University of Vermont College of Medicine Office of Clinical Trials Research

Open Clinical Trials

Many clinical trials are now looking for eligible participants.

The Insulin Resistance Intervention after Stroke Study

The IRIS Trial is a randomized clinical trial that will test the effectiveness of a new approach to preventing stroke and heart attack among patients with a recent ischemic stroke or TIA. The new approach targets insulin resistance, a newly-recongnized cause of atherosclerosis. Atherosclerosis is the underlying disease that clogs vessels in strokes and heart attacks, Insulin resistance affects nearly half of all patients with stroke and TIA.

Participating stroke patients will be assigned to receive piogliatzone, a medication which reduces insulin resistance, or placebo (an inactive look-alike pill). Patients will stay on their assigned treatment for about four years. At the end of the study, investigators will compare the experience of patients on pioglitazone and placebo to see which group had fewer recurrent and heart attacks.

You can read more information about the IRIS Trial or contact Cathy Gregory, R.N. at (802) 656-9094.

Last modified August 12 2013 03:50 PM